SEC Comment Letter for MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813) — Jul 16, 2020

MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813)
Date: July 16, 2020 · CIK: 0001267813 · Accession: 0000000000-20-006484

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-239780

Date

July 16, 2020

Author

Not clearly detected

Form

UPLOAD

Company

MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813)

Letter

United States securities and exchange commission logo July 16, 2020 Scott Braunstein, M.D. President and Chief Executive Officer Marinus Pharmaceuticals, Inc. 5 Radnor Corporate Center, Suite 500 100 Matsonford Rd Radnor, PA 19087 Re:Marinus Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed July 9, 2020 File No. 333-239780 Dear Dr. Braunstein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven J. Abrams, Esq.

Show Raw Text

United States securities and exchange commission logo
July 16, 2020
Scott Braunstein, M.D.
President and Chief Executive Officer
Marinus Pharmaceuticals, Inc.
5 Radnor Corporate Center, Suite 500
100 Matsonford Rd
Radnor, PA 19087
Re:Marinus Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed July 9, 2020
File No. 333-239780
Dear Dr. Braunstein:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Steven J. Abrams, Esq.

SecProbe.io